Compare Palantir Technologies Inc (PLTR) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palantir Technologies Inc vs Sanofi SA — how do they compare? Palantir Technologies Inc trades at $125.04 (market cap $318.03B), while Sanofi SA trades at $43.89 (market cap $104.85B). The key difference: Palantir Technologies Inc is far larger — about 3× Sanofi SA's market cap, and Sanofi SA pays a 5.53% dividend while Palantir Technologies Inc pays none. Which is the better fit depends on your goals.
| PLTR | SNY | |
|---|---|---|
Market Cap | $318.03B | $104.85B |
Sector | Technology | Health |
52-Week High | $207.18 | $52.34 |
52-Week Low | $107.27 | $41.33 |
Enterprise Value | $310.21B | $121.38B |
Dividend Yield | — | 5.53% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
